Still, the analysts predicted that Ozempic, Wegovy, and Rybelsus (semaglutide) maker Novo Nordisk and Eli Lilly, which developed Zepbound and Mounjaro (tirzepatide), will maintain two-thirds of the market by 2031 due to their first-mover advantages. Other competitors are expected to take a combined $70 billion of the GLP-1 market, the study read
But why is there even a need for such a medication
At Simply Direct Medicine in Farmers Branch, Texas, we help individuals achieve healthier lifestyles through medically supervised weight loss plans, including the use of Semaglutide
But here is where men face a unique challenge
The study's results added that "all cardiometabolic markers were projected to return to baseline within 1.4 years after the cessation" of weight management medications